A Study to Evaluate the Efficacy and Safety of Brenipatide in Adult Participants with Moderate-to-Severe COPD (RENEW-COPD)

Condition:  Chronic Obstructive Pulmonary Disease

Testing For: Brenipatide

Trial ID: J2S-MC-GZMV

Age: 40-75 Years old

Phase: 2

A Study Investigating Tersolisib (LY4064809) or Placebo Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with Breast Cancer with a PIK3CA Mutation

Condition:  Advanced Breast Cancer

A Phase 3, Randomized, Double‑blind, Placebo‑controlled Study of LY4064809 (tersolisib) in Combination with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2‑ Advanced Breast Cancer with a PIK3CA Mutation (PIKALO‑2)

A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Testing For: LY4064809 (Tersolisib)

Trial ID: J6M-MC-JSGD (PIKALO-2)

Age: 18+ years old

Phase: 2/3

A Phase 3 Study of Olomorasib in Combination with Standard of Care in Participants with Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)

Condition:  Non-Small Cell Lung Cancer

Testing For: olomorasib (LY3537982)

Trial ID: J3M-MC-JZQH

Age: 8+

Phase: 3

Condition:  Autoimmune Hepatitis

Help Advance Autoimmune Hepatitis (AIH) Research

Explore the MERCURY Study: Now enrolling adults with autoimmune hepatitis (AIH).

You may be eligible to join a clinical study exploring if a study drug may help control liver inflammation and reduce the long-term need for steroids in AIH.

Who Can Join
• Adults between the ages of 18–75
• Diagnosed with autoimmune hepatitis
• Symptoms that have not responded well or intolerant to current treatment options for AIH

Why Consider Participating
• Access to physicians with experience working with AIH
• Reasonable reimbursement for travel-related expenses
• The opportunity for eligible participants to receive the study drug during the optional open-label period

Learn More or See If You Qualify

A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/mirikizumab co-administration compared with mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

Condition:  Crohn’s Disease

Testing for: Mirikizumab (LY3074828) and LY4395089

Trial ID: J6Z-MC-CD01

Age: 18 to 80

Phase: 2

A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line Treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer (SUNRAY-02)

Condition:  Non-Small Cell Lung Cancer

Testing For: Olomorasib (LY3537982)

Trial ID: J3M-MC-JZQB

Age: Age: 18+

Study Title A Phase 3, randomized, modified double-blind, active controlled, parallel-group, 2-arm study to investigate the safety and immunogenicity of a single dose of a 21-valent pneumococcal conjugate vaccine in children and adolescents with sickle cell disease

Condition:  Sickle Cell Disease

Summary: this study is testing a new vaccine that protects against 21 types of pneumococcal bacteria. The study involves children and teenagers with sickle cell disease. Two-thirds of the participants will receive the new vaccine, and one-third will receive an existing, standard pneumococcal vaccine (the 'active control'). Participants are randomly assigned to groups. Researchers will compare how safe the new vaccine is and how well it helps the body's immune system fight disease. Each person gets 1 dose of the vaccine, and the study is designed so that neither the participants nor most of the researchers know who got which vaccine until the study is complete this helps ensure fair, unbiased results.

Age: 2-17

Phase: 3

A clinical trial for people who have irritable bowel syndrome with diarrhea (GZMS) (RENEW-IBS-D)

Condition:  Irritable Bowel Syndrome-Diarrhea (IBS-D)

What the trial is testing: Brenipatide

Trial ID: J3S-MC-GZMS

Age: 18 to 75 years of age

Phase: 2

A Clinical trial for people with irritable bowel syndrome with constipation (GZMT) (RENEW-IBS-C)

Condition:  Irritable Bowel Syndrome-Constipation (IBS-C)

What the trial is testing: Brenipatide

Trial ID: J3S-MC-GZMT

Age: 18 to 75 years of age

Phase: 2

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET).

Condition:  Crohn's Disease

A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease

Drugs: LY4268989 (MORF-057)

Trial ID: J6E-MC-KWAB

Age: 18 to 85

Phase: 2

Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

Condition:  Non-Segmental Vitiligo

Testing For: XCL1/2 (LY4005130)

Trial ID: J5D-MC-FPAD

Age: 18 to ≤75 years of age

Phase: 2

Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Severe Alopecia Areata

Condition:  Severe Alopecia Areata

Testing For: XCL1/2 (LY4005130)

Trial ID: J5D-MC-FPAC

Age: 18 to ≤50 years of age

Phase: 2